![Gideon E. Bollag](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gideon E. Bollag
Fundador en Opna Bio SA .
Cargos activos de Gideon E. Bollag
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Opna Bio SA
![]() Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Director/Miembro de la Junta | - | - |
Director Técnico/Científico/I+D | 01/07/2020 | - | |
Fundador | - | - |
Historial de carrera de Gideon E. Bollag
Antiguos cargos conocidos de Gideon E. Bollag.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Plexxikon, Inc.
![]() Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Director Ejecutivo | 01/05/2003 | 01/07/2021 |
Director Técnico/Científico/I+D | 01/06/2002 | - | |
Cetus Corp. | Corporate Officer/Principal | - | - |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Director/Miembro de la Junta | - | - |
Syrrx, Inc.
![]() Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Corporate Officer/Principal | - | - |
Formación de Gideon E. Bollag.
University of California, Berkeley | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Suiza | 2 |
Operativa
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Director/Board Member | 2 |
Sectorial
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Plexxikon, Inc.
![]() Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Commercial Services |
Syrrx, Inc.
![]() Syrrx, Inc. Pharmaceuticals: MajorHealth Technology Syrrx, Inc. used to develops drugs. Its focus was on creating novel therapies for cancer, metabolic diseases and inflammation. The company was the technology leader in the field of structural proteomics, the process of generating protein structures from genetic information. It was headquartered in San Diego, CA | Health Technology |
Onyx Pharmaceuticals, Inc.
![]() Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Cetus Corp. | Health Technology |
Opna Bio SA
![]() Opna Bio SA Pharmaceuticals: GenericHealth Technology Opna Bio is a clinical-stage biopharmaceutical company located in the US that focuses on discovering and developing novel oncology therapeutics. Opna's lead clinical compound, opn-2853, a bromo and extra terminal (bet) domain inhibitor, is currently in a phase 1/2 trial with ruxolitinib (jakafi®) in myelofibrosis, a chronic bone marrow disorder. The American company's team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market. The company has a broad portfolio that targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-x mental retardation protein (fmrp) and a diversified pipeline of validated oncology assets acquired from plexxikon. | Health Technology |
- Bolsa de valores
- Insiders
- Gideon E. Bollag
- Experiencia